159 related articles for article (PubMed ID: 21536014)
41. Typical achondroplasia secondary to a unique insertional variant of FGFR3 with in vitro demonstration of its effect on FGFR3 function.
Meyer AN; Modaff P; Wang CG; Wohler E; Sobreira NL; Donoghue DJ; Pauli RM
Am J Med Genet A; 2021 Mar; 185(3):798-805. PubMed ID: 33368972
[TBL] [Abstract][Full Text] [Related]
42. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.
Ronchetti D; Greco A; Compasso S; Colombo G; Dell'Era P; Otsuki T; Lombardi L; Neri A
Oncogene; 2001 Jun; 20(27):3553-62. PubMed ID: 11429702
[TBL] [Abstract][Full Text] [Related]
43. Kinase Activity of Fibroblast Growth Factor Receptor 3 Regulates Activity of the Papillomavirus E2 Protein.
Xie F; DeSmet M; Kanginakudru S; Jose L; Culleton SP; Gilson T; Li C; Androphy EJ
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768864
[TBL] [Abstract][Full Text] [Related]
44. FGFR3 intracellular mutations induce tyrosine phosphorylation in the Golgi and defective glycosylation.
Gibbs L; Legeai-Mallet L
Biochim Biophys Acta; 2007 Apr; 1773(4):502-12. PubMed ID: 17320202
[TBL] [Abstract][Full Text] [Related]
45. Neutron diffraction studies of fluid bilayers with transmembrane proteins: structural consequences of the achondroplasia mutation.
Han X; Mihailescu M; Hristova K
Biophys J; 2006 Nov; 91(10):3736-47. PubMed ID: 16950849
[TBL] [Abstract][Full Text] [Related]
46. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and forster resonance energy transfer suggest weak interactions between fibroblast growth factor receptor 3 (FGFR3) transmembrane domains in the absence of extracellular domains and ligands.
Li E; You M; Hristova K
Biochemistry; 2005 Jan; 44(1):352-60. PubMed ID: 15628877
[TBL] [Abstract][Full Text] [Related]
47. A simple "proximity" correction for Förster resonance energy transfer efficiency determination in membranes using lifetime measurements.
Posokhov YO; Merzlyakov M; Hristova K; Ladokhin AS
Anal Biochem; 2008 Sep; 380(1):134-6. PubMed ID: 18559252
[TBL] [Abstract][Full Text] [Related]
48. Suppression of severe achondroplasia with developmental delay and acanthosis nigricans by the p.Thr651Pro mutation.
Manickam K; Donoghue DJ; Meyer AN; Snyder PJ; Prior TW
Am J Med Genet A; 2014 Jan; 164A(1):243-50. PubMed ID: 24352917
[TBL] [Abstract][Full Text] [Related]
49. Mutant FGFR3 associated with SADDAN disease causes cytoskeleton disorganization through PLCγ1/Src-mediated paxillin hyperphosphorylation.
Montone R; Romanelli MG; Baruzzi A; Ferrarini F; Liboi E; Lievens PM
Int J Biochem Cell Biol; 2018 Feb; 95():17-26. PubMed ID: 29242050
[TBL] [Abstract][Full Text] [Related]
50. Different abilities of the four FGFRs to mediate FGF-1 translocation are linked to differences in the receptor C-terminal tail.
Sørensen V; Wiedlocha A; Haugsten EM; Khnykin D; Wesche J; Olsnes S
J Cell Sci; 2006 Oct; 119(Pt 20):4332-41. PubMed ID: 17003104
[TBL] [Abstract][Full Text] [Related]
51. Hill coefficient analysis of transmembrane helix dimerization.
Soong R; Merzlyakov M; Hristova K
J Membr Biol; 2009 Jul; 230(1):49-55. PubMed ID: 19603128
[TBL] [Abstract][Full Text] [Related]
52. Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition.
St-Germain JR; Taylor P; Tong J; Jin LL; Nikolic A; Stewart II; Ewing RM; Dharsee M; Li Z; Trudel S; Moran MF
Proc Natl Acad Sci U S A; 2009 Nov; 106(47):20127-32. PubMed ID: 19901323
[TBL] [Abstract][Full Text] [Related]
53. FGFR3 biology and skeletal disease.
Narayana J; Horton WA
Connect Tissue Res; 2015 Nov; 56(6):427-33. PubMed ID: 26075305
[TBL] [Abstract][Full Text] [Related]
54. Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells.
Meyer AN; McAndrew CW; Donoghue DJ
Cancer Res; 2008 Sep; 68(18):7362-70. PubMed ID: 18794123
[TBL] [Abstract][Full Text] [Related]
55. Unliganded fibroblast growth factor receptor 1 forms density-independent dimers.
Comps-Agrar L; Dunshee DR; Eaton DL; Sonoda J
J Biol Chem; 2015 Oct; 290(40):24166-77. PubMed ID: 26272615
[TBL] [Abstract][Full Text] [Related]
56. Kaempferol targeting on the fibroblast growth factor receptor 3-ribosomal S6 kinase 2 signaling axis prevents the development of rheumatoid arthritis.
Lee CJ; Moon SJ; Jeong JH; Lee S; Lee MH; Yoo SM; Lee HS; Kang HC; Lee JY; Lee WS; Lee HJ; Kim EK; Jhun JY; Cho ML; Min JK; Cho YY
Cell Death Dis; 2018 Mar; 9(3):401. PubMed ID: 29540697
[TBL] [Abstract][Full Text] [Related]
57. Effect of transmembrane and kinase domain mutations on fibroblast growth factor receptor 3 chimera signaling in PC12 cells. A model for the control of receptor tyrosine kinase activation.
Raffioni S; Zhu YZ; Bradshaw RA; Thompson LM
J Biol Chem; 1998 Dec; 273(52):35250-9. PubMed ID: 9857065
[TBL] [Abstract][Full Text] [Related]
58. The localization of FGFR3 mutations causing thanatophoric dysplasia type I differentially affects phosphorylation, processing and ubiquitylation of the receptor.
Bonaventure J; Horne WC; Baron R
FEBS J; 2007 Jun; 274(12):3078-93. PubMed ID: 17509076
[TBL] [Abstract][Full Text] [Related]
59. Crouzon syndrome with acanthosis nigricans and prominent diffuse hyperpigmentation associated with gain-of-function A391E mutation in FGFR3 gene.
Kariya H; Nakano H; Ishii N; Kaimi Y; Imai K; Nakanishi Y; Kunihiro N; Fukai K
J Dermatol; 2020 Dec; 47(12):e451-e452. PubMed ID: 32860240
[No Abstract] [Full Text] [Related]
60. Fibroblast growth factor receptor 3 (FGFR3) associated with the CD20 antigen regulates the rituximab-induced proliferation inhibition in B-cell lymphoma cells.
Kotani N; Ishiura Y; Yamashita R; Ohnishi T; Honke K
J Biol Chem; 2012 Oct; 287(44):37109-18. PubMed ID: 22932894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
